FDA approves first-ever RSV vaccine for older adults.

The FDA has approved the first-ever vaccine to combat severe respiratory syncytial virus (RSV), called Arexvy, developed by GlaxoSmithKline, for adults aged 60 and older. The vaccine was 82% effective at preventing lower respiratory tract illness caused by RSV and 94% effective in those with underlying medical conditions. RSV is the leading cause of hospitalizations among newborns and younger children and causes more than 177,000 hospitalizations and 14,000 deaths among older adults each year. Other RSV vaccines and treatments are also under review by regulatory agencies.